{ "Comparing Intra-arterial vs. IV Chemotherapy for Pancreatic Cancer", "This study is for people with locally advanced pancreatic cancer that cannot be removed by surgery. It compares two ways of giving chemotherapy (cancer-fighting drugs) after initial treatment with IV (into the vein) gemcitabine and nab-paclitaxel, plus radiation. One group will receive gemcitabine directly into the artery (intra-arterial) using a special catheter called RenovoCath. The other group will continue with IV gemcitabine and nab-paclitaxel. The main goal is to see which approach helps people live longer (Overall Survival), measured over five years. You may be able to join if you are 18 or older and have a confirmed diagnosis of pancreatic adenocarcinoma within a certain timeframe. The study is currently enrolling about 190 participants, but its exact status is unclear.", "design": "This is a multi-center, open-label (meaning you and your doctors will know which treatment you are receiving), randomized study comparing two treatment approaches. It plans to enroll about 190 participants.", "commitments": "You will first receive about four months of IV gemcitabine plus nab-paclitaxel and SBRT radiation therapy. Then, you will receive either intra-arterial gemcitabine or IV gemcitabine plus nab-paclitaxel for up to 16 weeks, followed by further treatment until disease progression.", "compensation": "Not stated in the trial record.", "follow_up": "You will be followed for survival for five years after the treatment course.", }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.